- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Newsflash: McKesson/HBOC drops three product lines
NEWSFLASH: McKesson/HBOC drops three product linesMcKesson/HBOC’s Information Technology Business is dropping three product lines as part of a major restructuring effort designed to refocus the company on its core healthcare information
NEWSFLASH: McKesson/HBOC drops three product lines
McKesson/HBOCs Information Technology Business is dropping three product lines as part of a major restructuring effort designed to refocus the company on its core healthcare information systems and information technologies business. The Alpharetta, GA-based company is discontinuing the Pathways Smart Medical Record for physician offices, Amisys Open managed-care system for payers, and PharmCare Windows-based pharmacy system. They are also suspending marketing efforts for the Paragon 2.9c HIS to address product performance issues.
McKesson/HBOC claims that these products have not met financial, quality, or customer satisfaction targets and that few customers will be affected by the product reorganization. The company intends to replace PharmCare with an updated product obtained through strategic alliance or acquisition and Pathways with the Web-based Abaton.com clinical EMR, which was recently obtained via acquisition. The firm also plans to enhance the Amisys 3000 product, including addressing HIPAA compliance.
Over the past 18 months, weve seen a slowdown in purchase decisions for these large, complex systems, said Glenn Rosenkoetter, president of ITBs Payer Solutions Group. We are revisiting our strategy for the high-end market and re-evaluating our delivery models.
Although all sales and marketing efforts for Paragon have been suspended, McKesson/HBOC plans to increase its investment in several other HIS products, including the Star 2000, Series 2000, and HealthQuest 2000, and to develop consulting services, an ASP service model, and an Internet-based environment for its current offerings. The company will likely seek strategic alliances for at least some of these new products, as indicated by its plans for the now-defunct PharmCare and Pathways.
© 2000 Miller Freeman, Inc., a United News & Media company.
- Search again
- Homepage
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
